Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 2/20 | 0.47 |
| ▸ | CCR5 | P51681 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5577553 | 0.88 | ABCB1 (0.51) | KDM4EALDH1A1APEX1ABCB1CHRM3 | |
| SCHEMBL5577413 | 0.88 | ABCB1 (0.54) | ABCB1CHRM3PDE10AACHECCR5 | |
| SCHEMBL5577476 | 0.87 | LMNA (0.55) | ABCB1CHRM3PDE10AACHECCR5 | |
| SCHEMBL5577329 | 0.86 | HPGD (0.54) | ABCB1CHRM3PDE10AACHECCR5 | |
| SCHEMBL5577878 | 0.85 | CHRM3 (0.52) | ABCB1CHRM3PDE10AACHECCR5 | |
| SCHEMBL5577689 | 0.85 | CCR5 (0.61) | ALDH1A1ABCB1ACHECCR5BCHE | |
| SCHEMBL5577417 | 0.85 | NR1H4 (0.58) | ALDH1A1ABCB1ACHECCR5BCHE | |
| SCHEMBL5577667 | 0.84 | PTBP1 (0.51) | ALDH1A1DRD3ABCB1PDE10AACHE | |
| SCHEMBL5577744 | 0.84 | ABCB1 (0.49) | KDM4EALDH1A1ABCB1CHRM3PDE10A | |
| SCHEMBL5577508 | 0.84 | DRD2 (0.58) | ABCB1CHRM3ACHECCR5BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| EP-1616862-A1 | NITROGENOUS HETEROCYCLIC COMPOUND AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043079-A1 | Heterocyclic compound containing nitrogen atom and use thereof | HLA-DRB1, MIF, HLA-C | KDM4E 4213/4885ALDH1A1 1147/4885DRD3 4080/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.